Branch-like enhancement on contrast enhanced MRI is a specific finding of cerebellar lymphoma compared with other pathologies.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 03 2022
04 03 2022
Historique:
received:
02
09
2021
accepted:
18
02
2022
entrez:
5
3
2022
pubmed:
6
3
2022
medline:
15
4
2022
Statut:
epublish
Résumé
Branch-like enhancement (BLE) on contrast-enhanced (CE) magnetic resonance imaging (MRI) was found to be effective in differentiating primary central nervous system lymphoma (PCNSL) from high-grade glioma (HGG) in the cerebellum. However, whether it can be applied to assessments of secondary central nervous system lymphoma (SCNSL), or other cerebellar lesions is unknown. Hence, we retrospectively reviewed cerebellar masses to investigate the use of BLE in differentiating cerebellar lymphoma (CL), both primary and secondary, from other lesions. Two reviewers qualitatively evaluated the presence and degree of BLE on CE-T1 weighted imaging (T1WI). If multiple views were available, we determined the view in which BLE was the most visible. Seventy-five patients with the following pathologies were identified:17 patients with CL, 30 patients with metastasis, 12 patients with hemangioblastoma, 9 patients with HGG, and 7 patients with others. Twelve patients presented with PCNSL and five with SCNSL. Of 17 patients with CL, 15 (88%) had BLE, whereas three (5%) out of 58 patients in the non-CL group showed BLE. In patients who underwent three-dimensional-CE-T1WI, BLE was the most visible on the sagittal image. In conclusion, BLE is a highly specific finding for CL and the sagittal image is important in evaluating this finding.
Identifiants
pubmed: 35246572
doi: 10.1038/s41598-022-07581-x
pii: 10.1038/s41598-022-07581-x
pmc: PMC8897486
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3591Informations de copyright
© 2022. The Author(s).
Références
Leuk Lymphoma. 2011 Oct;52(10):2007-9
pubmed: 21663503
Radiology. 2014 Sep;272(3):843-50
pubmed: 24814181
Neuropsychiatr Dis Treat. 2018 Mar 12;14:733-740
pubmed: 29559780
Neurology. 2001 Aug 14;57(3):393-6
pubmed: 11515505
Leuk Lymphoma. 2014 Oct;55(10):2228-40
pubmed: 24286262
Turk Neurosurg. 2015;25(5):796-800
pubmed: 26442550
JAMA Neurol. 2013 Mar 1;70(3):311-9
pubmed: 23319132
Clin Radiol. 2019 Apr;74(4):268-277
pubmed: 30691731
Brain. 2010 Sep;133(9):2626-34
pubmed: 20639547
Neurol Sci. 2019 Mar;40(3):535-542
pubmed: 30580380
Hematol Oncol Clin North Am. 2005 Aug;19(4):751-63, viii
pubmed: 16083835
J Clin Oncol. 2005 Aug 1;23(22):5034-43
pubmed: 15955902
Radiology. 2014 Aug;272(2):504-13
pubmed: 24697149
Br J Cancer. 2011 Oct 25;105(9):1414-8
pubmed: 21915121
Clin Radiol. 2016 Oct;71(10):1018-1029
pubmed: 27341986
J Magn Reson Imaging. 2019 Aug;50(2):560-572
pubmed: 30637843
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
pubmed: 22237781
AJNR Am J Neuroradiol. 2011 Jun-Jul;32(6):984-92
pubmed: 20616176
AJNR Am J Neuroradiol. 2018 Feb;39(2):273-279
pubmed: 29301782
AJNR Am J Neuroradiol. 2013 Jan;34(1):35-40
pubmed: 22936096
Neuroradiol J. 2021 Dec;34(6):575-584
pubmed: 33949230
Am J Hematol. 2013 Dec;88(12):997-1000
pubmed: 23873804
Neuroradiology. 1993;35(6):454-6
pubmed: 8377920
Lancet. 2011 Nov 12;378(9804):1741-55
pubmed: 21565397
Leuk Lymphoma. 2014 Mar;55(3):509-14
pubmed: 23741977
Int J Hematol. 2006 Aug;84(2):128-35
pubmed: 16926134
Rev Assoc Med Bras (1992). 2019 Feb;65(2):136-140
pubmed: 30892435
Sci Rep. 2020 Jun 19;10(1):10007
pubmed: 32561819
BMC Neurol. 2019 Nov 4;19(1):268
pubmed: 31684888
Neuro Endocrinol Lett. 2016 Sep;37(4):318-324
pubmed: 27857050
J Neurooncol. 2018 Oct;140(1):1-4
pubmed: 29998396
Eur Radiol. 2021 Apr;31(4):1863-1871
pubmed: 32997181
AJNR Am J Neuroradiol. 2009 Apr;30(4):744-51
pubmed: 19164442